Rubius Therapeutics Inc (NASDAQ:RUBY) Receives Consensus Rating of “Buy” from Analysts

Rubius Therapeutics Inc (NASDAQ:RUBY) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $25.00.

Several equities research analysts have recently commented on RUBY shares. JPMorgan Chase & Co. reduced their target price on shares of Rubius Therapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, August 29th. HC Wainwright assumed coverage on shares of Rubius Therapeutics in a research report on Wednesday, June 26th. They set a “buy” rating and a $40.00 target price for the company. Robert W. Baird began coverage on shares of Rubius Therapeutics in a research report on Monday. They set an “underperform” rating and a $4.00 target price for the company. Guggenheim began coverage on shares of Rubius Therapeutics in a research report on Thursday, May 30th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Rubius Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 24th.

In other Rubius Therapeutics news, Director Robert Langer sold 7,500 shares of Rubius Therapeutics stock in a transaction on Monday, July 15th. The stock was sold at an average price of $14.94, for a total value of $112,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher L. Carpenter sold 47,757 shares of the business’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total value of $669,553.14. The disclosure for this sale can be found here. Company insiders own 58.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Jennison Associates LLC grew its holdings in Rubius Therapeutics by 0.4% during the 1st quarter. Jennison Associates LLC now owns 479,398 shares of the company’s stock worth $8,677,000 after acquiring an additional 1,802 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Rubius Therapeutics during the second quarter worth approximately $46,000. Tower Research Capital LLC TRC acquired a new position in shares of Rubius Therapeutics during the second quarter worth approximately $67,000. Metropolitan Life Insurance Co NY lifted its position in shares of Rubius Therapeutics by 65.0% during the first quarter. Metropolitan Life Insurance Co NY now owns 11,867 shares of the company’s stock worth $214,000 after purchasing an additional 4,676 shares in the last quarter. Finally, MetLife Investment Advisors LLC grew its stake in shares of Rubius Therapeutics by 52.2% during the first quarter. MetLife Investment Advisors LLC now owns 16,410 shares of the company’s stock valued at $297,000 after purchasing an additional 5,629 shares during the last quarter. Institutional investors own 97.74% of the company’s stock.

RUBY stock traded up $1.04 during trading on Friday, hitting $9.79. The company had a trading volume of 314,322 shares, compared to its average volume of 269,685. The company has a fifty day moving average price of $10.96 and a two-hundred day moving average price of $14.76. The company has a current ratio of 17.27, a quick ratio of 17.27 and a debt-to-equity ratio of 0.21. The company has a market cap of $755.89 million, a P/E ratio of -4.31 and a beta of 2.25. Rubius Therapeutics has a fifty-two week low of $8.54 and a fifty-two week high of $24.49.

Rubius Therapeutics (NASDAQ:RUBY) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.04). During the same period in the previous year, the business posted ($3.33) earnings per share. On average, analysts expect that Rubius Therapeutics will post -2.02 earnings per share for the current year.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Featured Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.